Privium Fund Management B.V. Neoleukin Therapeutics, Inc. Transaction History

Privium Fund Management B.V.

  • $401 Million
  • Q3 2024

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Jul 25, 2023
BUY
$0.68 - $0.91 $79,696 - $106,652
117,200 New
117,200 $97,000

Others Institutions Holding NLTX

# of Institutions
1
Shares Held
199K
Call Options Held
0
Put Options Held
0
View Full List

About Neoleukin Therapeutics, Inc.

NLTX Quotes by TradingView
  • Ticker NLTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 42,579,900
  • Description
  • Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of vario...
More about NLTX
Track This Portfolio

Track Privium Fund Management B.V. Portfolio

Follow Privium Fund Management B.V. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Privium Fund Management B.V., based on Form 13F filings with the SEC.

News

Stay updated on Privium Fund Management B.V. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email